Pfizer Inc. PFE, -1.73% said Friday that the U.S. Food and Drug Administration has approved the first five-in-one vaccine designed to protect teenagers and young adults against meningococcal…
Read more Pfizer gets FDA green light for new shot that can streamline teenagers’ vaccinationsIf 80% of children ages 5 and older get their COVID booster shots by the end of 2022, it could prevent about 29 million missed days of school…
Read more A robust booster campaign could prevent millions of missed school days among children ages 5 to 17, report findsA number of young children are being hospitalized because of respiratory syncytial virus, or RSV, and it’s happening at an unusual time of year and among older children…
Read more COVID-19 may be to blame for the surge in RSV illness among children. Here’s why.
